Category
58 releases
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd)…
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often…
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up…
Made Scientific to integrate multiple UniFuge® single-use centrifugation systems across its Princeton, NJ, and East Norriton, PA, facilities to…
Sword Bio and Alturas Analytics today announced a strategic collaboration designed to provide biotechnology and pharmaceutical companies with…
Northwest Biotherapeutics (OTCQB: NWBO) NWBio a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,…
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding…
A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows. The drug, called…
COVID-19 experience raises questions about manufacturing, biological persistence and long-term safety OCALA, Fla., Oct. 26, 2026 — Gerry A. Quinn,…
Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins…
As drug pipelines grow faster than site capacity, Florence moves from storing trial work to doing it, with research teams in charge of the decisions…
In this free webinar, explore the potential of extracellular vesicles and particles (EVPs) as liquid biopsy analytes for early cancer detection.…
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings…
In this free webinar, learn how major findings from ESMO 2026 could influence cancer treatment and oncology drug development. The featured speakers…
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to…
Celebrating the clinically proven treatment that has become the leader*1 in professional microneedling NASHVILLE, Tenn., Oct. 26, 2026 — Revance, a…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. Ex vivo data in two models of…
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human…
No dose-limiting toxicities and no Grade ≥2 treatment-emergent adverse events through four dose levels; Plasma exposures exceed those predicted by…
